FKTN Antibody

What is FKTN and what is its primary function in cellular biology?

FKTN (Fukutin) functions as a ribitol-phosphate transferase that catalyzes the transfer of ribitol-phosphate from CDP-ribitol to the distal N-acetylgalactosamine of the phosphorylated O-mannosyl trisaccharide, a carbohydrate structure present in alpha-dystroglycan (DAG1) . This constitutes the first step in forming the ribitol 5-phosphate tandem repeat that links the phosphorylated O-mannosyl trisaccharide to the ligand binding moiety composed of repeats of 3-xylosyl-alpha-1,3-glucuronic acid-beta-1 . The protein is essential for normal glycosylation of alpha-dystroglycan in skeletal muscle, with mutations causing a spectrum of muscular dystrophies including Fukuyama congenital muscular dystrophy (FCMD) . FKTN is also required for normal localization and activity of POMGNT1 in Golgi membranes and may interact with a large protein complex spanning muscle membranes . Current evidence suggests FKTN has potential involvement in brain development, making it a protein of interest across multiple biological systems .

Where is FKTN protein localized within cellular compartments?

FKTN protein is predominantly localized in the cis-Golgi compartment of cells . This localization is critical for its function as a glycosyltransferase involved in the post-translational modification of proteins, particularly alpha-dystroglycan. The protein's targeted distribution in the cis-Golgi enables it to participate in the early stages of the glycosylation pathway, where it adds specific sugar modifications to substrate proteins . Proper Golgi localization of FKTN is essential for its enzymatic activity, as mislocalization can lead to glycosylation defects even when the protein is otherwise intact. For experimental validation of FKTN localization, researchers typically perform co-localization studies using immunofluorescence with FKTN antibodies alongside known Golgi markers to confirm the subcellular distribution pattern .

What is the molecular weight and structure of human FKTN protein?

Human FKTN (Fukutin) has a molecular weight of approximately 53.7 kDa . The protein functions as a glycosyltransferase with specific enzymatic activity transferring ribitol-phosphate. While the complete three-dimensional structure has not been fully characterized in the provided search results, FKTN contains functional domains necessary for its catalytic activity as a ribitol-5-phosphate transferase . When running Western blots to detect FKTN, researchers should expect bands around the 54 kDa mark, though post-translational modifications may affect migration patterns in gel electrophoresis. For experimental design purposes, researchers should consider this molecular weight when setting up gel systems, transfer conditions, and when evaluating antibody specificity through Western blotting procedures. Validation of antibody specificity is crucial when studying FKTN, as non-specific binding can lead to misinterpretation of experimental results .

What FKTN antibodies are available for research and what are their key characteristics?

Several validated FKTN antibodies are available for research applications, each with distinct characteristics. The MANFU5-7H2 is a mouse monoclonal antibody (IgG2a isotype) developed against full-length recombinant human FKTN protein, deposited at the Developmental Studies Hybridoma Bank (DSHB) by G.E. Morris from the Wolfson Centre for Inherited Neuromuscular Disease . This antibody has confirmed reactivity with human FKTN and is recommended for immunofluorescence and Western blot applications . The antibody registry ID is AB_2618197, which allows for standardized citation in publications .

Another available option is the rabbit recombinant monoclonal antibody EPR7913 (ab131280) from Abcam, which has been cited in at least four publications and is suitable for immunohistochemistry on paraffin-embedded samples (IHC-P) and Western blotting (WB) . This antibody also shows specificity for human samples .

For experimental design, researchers should select antibodies based on their specific applications, considering factors such as host species (to avoid cross-reactivity in multi-labeling experiments), clonality (monoclonal for specific epitopes, polyclonal for broader detection), and validated applications in the literature. Proper controls should be included to validate specificity in each experimental system .

What are the recommended applications and protocols for FKTN antibodies?

FKTN antibodies have been validated for several research applications, with specific recommendations depending on the antibody clone. For the MANFU5-7H2 mouse monoclonal antibody, the recommended applications include immunofluorescence and Western blotting . When performing Western blot analysis, researchers should use standard SDS-PAGE protocols looking for a band at approximately 53.7 kDa . For optimal results, follow manufacturer guidelines regarding antibody dilution, blocking solutions, and incubation times.

For immunofluorescence applications, FKTN antibodies can be used to visualize the protein's localization in the cis-Golgi compartment. This application is particularly useful for studying the trafficking and subcellular distribution of wild-type and mutant FKTN proteins . Co-staining with Golgi markers can provide additional confirmation of proper localization.

The EPR7913 rabbit recombinant monoclonal antibody is suitable for immunohistochemistry on paraffin-embedded tissues (IHC-P) in addition to Western blotting . This extends the range of applications to include analysis of FKTN expression in patient tissue samples.

For all applications, researchers should include appropriate positive and negative controls to validate antibody specificity. When planning experimental designs, consider the cellular localization of FKTN in the Golgi apparatus, which may require specific fixation and permeabilization protocols to maintain structural integrity while ensuring antibody accessibility .

How should researchers optimize Western blot protocols for FKTN detection?

Optimizing Western blot protocols for FKTN detection requires careful consideration of several factors. First, protein extraction methods should preserve the integrity of membrane-associated proteins like FKTN. Using buffers containing mild detergents such as CHAPS or NP-40 can help solubilize FKTN without denaturing its structure. Since FKTN is a Golgi-resident protein, membrane fraction enrichment techniques may improve detection sensitivity .

Sample preparation should include protease inhibitors to prevent degradation during extraction. For gel electrophoresis, 8-10% acrylamide gels typically provide good resolution for the 53.7 kDa FKTN protein . Transfer conditions may need optimization for glycosylated proteins; using PVDF membranes and extending transfer time or using semi-dry transfer systems can improve efficiency.

Blocking with 5% non-fat milk in TBST is generally effective, though 5% BSA may reduce background in some cases. Primary antibody dilutions should follow manufacturer recommendations; for MANFU5-7H2, starting with 1:500 to 1:1000 dilutions is reasonable, with overnight incubation at 4°C . Secondary antibody selection should match the primary antibody host species (anti-mouse for MANFU5-7H2, anti-rabbit for EPR7913) .

For challenging samples with low FKTN expression, enhanced chemiluminescence detection systems with longer exposure times may be necessary. When interpreting results, remember that glycosylation states may affect protein migration patterns, potentially resulting in bands appearing at slightly different molecular weights than predicted .

How can FKTN antibodies be used to study dystroglycanopathies and muscular dystrophies?

FKTN antibodies serve as crucial tools for investigating dystroglycanopathies, particularly Fukuyama congenital muscular dystrophy (FCMD) and limb-girdle muscular dystrophy, which result from FKTN mutations . Researchers can employ these antibodies to assess FKTN protein expression levels and localization in patient-derived tissues and cell models. In Western blot analysis, comparing FKTN protein quantity between patient and control samples can reveal deficiencies associated with pathogenic mutations .

For more sophisticated applications, FKTN antibodies can be used alongside antibodies against glycosylated α-dystroglycan to establish correlations between FKTN expression and α-dystroglycan glycosylation status . This is particularly valuable because α-dystroglycan glycosylation serves as a functional readout of FKTN activity. In studies examining therapeutic approaches, such as antisense oligonucleotide (AON) treatments targeting aberrant FKTN splicing, researchers can measure restored FKTN protein levels using specific antibodies .

Immunofluorescence microscopy using FKTN antibodies allows visualization of the protein's subcellular localization, helping determine whether mutations affect proper Golgi targeting . Co-localization studies with markers for different Golgi compartments can provide insight into trafficking defects. For functional studies, researchers can correlate FKTN localization with glycosylation enzyme activity and subsequent α-dystroglycan modification, forming a comprehensive understanding of the pathomechanisms underlying dystroglycanopathies .

What methods are available for studying aberrant FKTN splicing and how can antibodies complement these approaches?

Studying aberrant FKTN splicing involves a multi-faceted approach where antibodies play a complementary role to molecular techniques. RT-PCR analysis serves as the primary method for detecting abnormal splicing patterns, as demonstrated in studies of the c.647+2084G>T FKTN variant that creates a pseudo-exon with a premature stop codon in FCMD patients . Researchers can design primers flanking suspected regions of mis-splicing to amplify and visualize normal and aberrant transcripts through gel electrophoresis. Direct sequencing of RT-PCR products confirms the precise nature of splicing alterations, such as the 64-bp pseudo-exon insertion between exons 5 and 6 observed in FCMD .

FKTN antibodies complement these molecular approaches by assessing whether aberrant splicing affects protein expression. Western blotting with FKTN antibodies can determine if mis-spliced transcripts are translated into truncated proteins or trigger nonsense-mediated decay, resulting in reduced protein levels . In therapeutic development, such as antisense oligonucleotide (AON) approaches targeting branch points (BPs) to correct splicing defects, antibodies provide crucial validation of restored protein expression .

How can researchers use α-dystroglycan glycosylation as a surrogate marker for FKTN function?

α-Dystroglycan (α-DG) glycosylation status serves as an effective surrogate marker for FKTN functional activity in research settings, particularly when direct FKTN protein detection proves challenging with available antibodies . This approach leverages FKTN's critical role in transferring ribitol-phosphate to the phosphorylated O-mannosyl trisaccharide on α-DG, which is essential for proper glycosylation . When FKTN function is compromised by mutations or altered expression, α-DG glycosylation becomes significantly reduced, producing a measurable phenotype.

For experimental implementation, researchers should employ Western blotting with antibodies specifically recognizing glycosylated forms of α-DG, such as IIH6 or VIA4-1 antibodies. These antibodies bind to glycoepitopes present only when proper glycosylation has occurred . Parallel immunofluorescence staining of cultured cells or tissue sections provides spatial information about glycosylation patterns. In functional recovery studies, such as those employing antisense oligonucleotides to correct FKTN splicing defects, researchers have successfully used increased glycosylated α-DG levels as evidence of restored FKTN activity .

The methodology requires careful consideration of controls, including samples from patients with confirmed FKTN mutations showing reduced glycosylation, and samples from individuals without neuromuscular disease showing normal glycosylation patterns . When quantifying Western blot results, researchers should normalize glycosylated α-DG signals to total α-DG or other loading controls to account for variations in protein loading. This approach proves particularly valuable in therapeutic development pipelines where the functional restoration of glycosylation pathways represents the ultimate goal of intervention strategies .

What controls should be included when using FKTN antibodies in experimental designs?

When designing experiments with FKTN antibodies, incorporating appropriate controls is essential for result validation and interpretation. For Western blot applications, researchers should include positive controls consisting of tissue or cell lysates known to express FKTN, such as skeletal muscle samples or appropriate cell lines . Negative controls should include samples from tissues where FKTN expression is minimal or absent. When studying patient samples with suspected FKTN mutations, comparisons with age-matched control samples are critical for appropriate interpretation .

For antibody validation, include a loading control that normalizes for total protein content, such as GAPDH, β-actin, or total protein staining methods like Ponceau S. Consider including a recombinant FKTN protein standard if available to confirm antibody specificity and provide quantitative reference . For genetic studies involving FKTN mutations, samples from patients with confirmed molecular diagnoses serve as valuable positive controls .

In immunofluorescence or immunohistochemistry experiments, include secondary-only controls to assess non-specific binding. Peptide competition assays, where the antibody is pre-incubated with excess antigen before application, can confirm signal specificity . For studies investigating FKTN's role in α-dystroglycan glycosylation, parallel staining with antibodies against glycosylated α-dystroglycan provides functional correlation .

When examining experimental therapies targeting FKTN, such as splicing modulators or antisense oligonucleotides, untreated patient cells provide critical baseline controls, while cells from healthy donors establish normal reference ranges . These comprehensive controls ensure robust interpretation of experimental outcomes and address potential technical and biological variables.

What are common challenges in detecting FKTN protein and how can researchers overcome them?

Detecting FKTN protein presents several challenges that researchers must address through methodological refinements. One primary difficulty is the relatively low endogenous expression level of FKTN in many cell types, which necessitates sensitive detection methods . To overcome this limitation, researchers can employ enhanced chemiluminescence systems for Western blotting or consider using protein concentration techniques before analysis. Signal amplification methods, such as tyramide signal amplification for immunohistochemistry, can improve detection sensitivity significantly.

Antibody specificity issues represent another common challenge. The search results indicate that commercially available anti-FKTN antibodies may not always provide sufficient sensitivity for direct detection in patient-derived cells . Researchers should validate antibodies using positive and negative controls, including recombinant FKTN protein expression systems or FKTN-knockout cell lines when available. Testing multiple antibody clones targeting different epitopes may identify optimal reagents for specific applications.

FKTN's localization in the Golgi apparatus presents technical challenges for fixation and permeabilization protocols in immunocytochemistry . Optimizing fixation methods (e.g., comparing paraformaldehyde, methanol, or acetone fixation) and testing different permeabilization agents (e.g., Triton X-100, saponin, or digitonin) can improve antibody accessibility while preserving Golgi structure. For challenging samples, alternative approaches include using surrogate markers such as α-dystroglycan glycosylation status, which reflects FKTN enzymatic activity .

Post-translational modifications may affect antibody epitope recognition and protein migration patterns in gel electrophoresis. Researchers should consider using different extraction methods and buffer systems that preserve protein modifications. When interpreting results with patient samples, remember that pathogenic mutations may affect protein stability and expression levels, potentially requiring longer exposure times for detection .

How can researchers design experiments to study FKTN's role in the glycosylation pathway?

Designing experiments to elucidate FKTN's role in the glycosylation pathway requires a multifaceted approach combining genetic, biochemical, and cell biological techniques. Start with cellular models expressing wild-type and mutant FKTN variants, using patient-derived cells (e.g., myoblasts or fibroblasts) or engineered cell lines with CRISPR/Cas9-mediated FKTN modifications . These systems allow comparison of glycosylation patterns between normal and pathological conditions.

For functional analysis, assessing α-dystroglycan glycosylation serves as a primary readout of FKTN activity . Implement Western blotting with glycosylation-specific antibodies (e.g., IIH6 or VIA4-1) alongside immunofluorescence microscopy to evaluate both quantity and cellular distribution of glycosylated proteins. Laminin overlay assays can further assess the functional consequences of altered glycosylation on extracellular matrix protein binding.

To investigate FKTN's enzymatic function as a ribitol-phosphate transferase, design in vitro glycosylation assays using purified components . This approach allows direct measurement of FKTN's catalytic activity and can reveal how specific mutations affect enzyme kinetics. Mass spectrometry analysis of glycopeptides from α-dystroglycan can provide detailed structural information about glycan modifications in different experimental conditions.

For understanding FKTN's interactions with other glycosylation pathway components, co-immunoprecipitation experiments using FKTN antibodies can identify protein binding partners . Proximity labeling approaches (e.g., BioID or APEX) offer alternatives for capturing transient interactions within the Golgi environment. To study FKTN's impact on POMGNT1 localization and activity, design co-localization studies using immunofluorescence microscopy with markers for different Golgi compartments .

When investigating therapeutic approaches like antisense oligonucleotides for correcting aberrant FKTN splicing, design comprehensive assays that measure effects at multiple levels: RNA splicing patterns (RT-PCR), protein expression (Western blot), and functional outcomes (α-dystroglycan glycosylation) . This multilevel analysis provides robust evidence for mechanism-based interventions targeting FKTN-related disorders.

What progress has been made in developing therapeutic strategies targeting FKTN-related disorders?

Recent research has yielded promising therapeutic strategies for FKTN-related disorders, particularly focusing on correcting aberrant splicing caused by pathogenic mutations. A significant breakthrough involves antisense oligonucleotides (AONs) targeting branch points (BPs) in pre-mRNA splicing . In one approach, researchers developed BP-targeted AONs for the common FKTN c.647+2084G>T variant that creates a pseudo-exon with a premature stop codon in Fukuyama congenital muscular dystrophy (FCMD) . These BP-AONs successfully restored normal FKTN mRNA and protein production in patient-derived myotubes, demonstrating potential clinical applicability.

Importantly, researchers extended this approach to another FCMD-causing variant that induces exon trapping by a common SINE-VNTR-Alu-type retrotransposon, demonstrating the versatility of BP-targeted therapies . The success of these approaches was validated by showing increased glycosylation of α-dystroglycan, confirming functional restoration of the glycosylation pathway . These findings establish branch points as promising therapeutic targets for exon-skipping strategies in genetic disorders beyond FKTN-related conditions, potentially expanding treatment options for a broader range of diseases characterized by aberrant splicing.

How do FKTN mutations contribute to the pathogenesis of dystroglycanopathies?

FKTN mutations contribute to dystroglycanopathy pathogenesis through disruption of the protein's essential role in alpha-dystroglycan (α-DG) glycosylation. FKTN functions as a ribitol-phosphate transferase that catalyzes a critical step in forming the ribitol 5-phosphate tandem repeat linking the phosphorylated O-mannosyl trisaccharide to the ligand binding moiety in α-DG . When FKTN is mutated, this glycosylation process becomes compromised, leading to hypoglycosylated α-DG that cannot effectively bind extracellular matrix components like laminin, causing membrane instability and subsequent muscle damage .

Different mutation types produce varying disease severities. The most common mutation in Japanese FCMD patients is a founder mutation involving a SINE-VNTR-Alu retrotransposon insertion that causes aberrant splicing . Other mutations include point mutations like c.647+2084G>T that create pseudo-exons with premature stop codons . The c.340G>A and c.527T>C variants, predicting missense mutations p.A114T and p.F176S respectively, have been identified in childhood-onset limb-girdle muscular dystrophy, representing milder phenotypes despite substantial α-DG hypoglycosylation .

Beyond direct effects on α-DG glycosylation, FKTN mutations disrupt normal localization of POMGNT1 in Golgi membranes and compromise its activity . This creates a cascade effect where multiple enzymes in the glycosylation pathway become dysregulated. Research suggests FKTN may also participate in a larger complex spanning muscle membranes, with mutations potentially destabilizing this structural arrangement . Additionally, FKTN is implicated in brain development, explaining the central nervous system involvement seen in more severe dystroglycanopathies . This multifaceted pathogenesis highlights why therapeutic strategies targeting FKTN can potentially address multiple downstream disease manifestations.

What methodologies are emerging for studying FKTN function and developing targeted therapies?

Emerging methodologies for studying FKTN function and developing targeted therapies integrate advanced molecular techniques with functional assays. Luminescence-based reporter systems have been developed to analyze splicing modifications, such as the FKTN splicing reporter with a HiBiT tag that emits bright luminescence upon proper splicing . This system allows high-throughput screening of compounds affecting splicing regulation with quantitative readouts (z' factor = 0.90) and has successfully identified SF3B1 inhibitors as modulators of FKTN splicing .

For therapeutic development, branchpoint-targeted antisense oligonucleotides (BP-AONs) represent an innovative approach . Researchers have identified functional branchpoints by detecting splicing intermediates and creating BP mutations in reporter genes. This knowledge enabled design of specific BP-AONs that restored normal FKTN mRNA and protein production in FCMD patient myotubes by promoting exclusion of the pathogenic pseudo-exon . The methodology involved careful titration experiments to determine optimal oligonucleotide concentrations and chemical modifications for cellular efficacy.

When direct detection of FKTN protein proves challenging, researchers have implemented surrogate markers such as α-dystroglycan glycosylation status . This approach uses Western blotting and immunofluorescence staining with glycosylation-specific antibodies to assess the functional outcome of therapeutic interventions. The methodology includes quantitative image analysis of glycosylated α-DG signal intensity in treated versus untreated conditions .

CRISPR/Cas9 gene editing technologies offer another emerging approach for studying FKTN function through creation of isogenic cell lines with specific mutations or corrections. This allows precise analysis of mutation-specific effects while controlling for genetic background variability. For a comprehensive understanding of FKTN's role in the glycosylation pathway, mass spectrometry-based glycoproteomics methodologies enable detailed structural characterization of glycan modifications on α-dystroglycan and other potential substrates, providing insights that can inform targeted therapy design .